Antengene

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

Antengene Selected as a Constituent of the FTSE Global Equity Index Series

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Index-es Including the Hang Seng Composite Index

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Antengene Submits NDAs for XPOVIO(R) (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

Antengene Corporation Limited Announces Proposed Listing on the Main Board of SEHK Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Near-term Commercialization Launch Prospects of Core Products Offer price between HK$15.80 and HK$18.08 per share

Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer